๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-03-18

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors (NCT05948865)

A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients With Advanced or Metastatic Solid Tumors

๐ŸŸข Recruiting Phase1 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: Conjupro Biotherapeutics, Inc.

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors. The main questions it aims to answer are: * To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A) * To assess the safety and tolerability of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and potentially other tumor types (Part B) * To evaluate how quickly CPO301 is metabolized by the body (pharmacokinetics or PK) * To evaluate if antibodies to the study drug develop (immunogenicity) * To evaluate preliminary efficacy to the drug * To correlate preliminary efficacy with mutations in a biomarker called EGFR Participants will: * Provide written informed consent * Undergo screening tests to ensure they are eligible for study treatment * Attend all required study visits and receive CPO301 by intravenous injection every 3 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment * Be followed for progression every 3 months for up to 2 years

Who can join: Review the eligibility criteria below.

Location: USC Norris Comprehensive Cancer Center โ€” Los Angeles, California

Age range: 18 Years

๐Ÿงช Interventions in This Study

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (14 Sites)

  • USC Norris Comprehensive Cancer Center โ€” Los Angeles, California
  • Hoag Memorial Hospital Presbyterian โ€” Newport Beach, California
  • UCLA Hematology/Oncology - Santa Monica โ€” Santa Monica, California
  • Sarah Cannon Research Institute (SCRI) at HealthONE โ€” Denver, Colorado
  • AdventHealth Cancer Institute โ€” Celebration, Florida
  • Florida Cancer Specialists โ€” Sarasota, Florida
  • Dartmouth Hitchcock Medical Center โ€” Lebanon, New Hampshire
  • Fox Chase Cancer Center โ€” Philadelphia, Pennsylvania
  • SCRI Oncology Partners โ€” Nashville, Tennessee
  • NEXT Dallas โ€” Dallas, Texas
  • NEXT Virginia โ€” Fairfax, Virginia
  • Cross Cancer Institute โ€” Edmonton, Alberta
  • Juravinski Cancer Centre โ€” Hamilton, Ontario
  • Princess Margaret Cancer Centre - University Health Network โ€” Toronto, Ontario

๐Ÿ“ž Contact the Study Coordinator

Phone: (609) 686-6502

Email: clinicaltrials.gov@cspcus.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Cancer clinical trials

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—